Business Context and Reporting Period
NewGenIvf Group Limited filed this Form 6-K on October 7, 2026, announcing a planned reverse stock split. The filing does not report operating or financial results for a reporting period.
Key Terms and Share Impact
- The board approved a 1-for-4 reverse split of all issued and unissued shares, including Class A ordinary shares, Class B ordinary shares, and preferred shares. The ratio may be otherwise determined by the CEO.
- The split is scheduled to take effect at 12:01 a.m. ET on October 12, 2026. Class A shares are expected to begin split-adjusted Nasdaq trading at market open that day.
- Based on shares outstanding as of October 6, the company expects Class A shares outstanding to decrease from approximately 35,688,329 to approximately 8,922,083. The actual total may be higher on the effective date due to shares issued upon convertible note exercises.
- No fractional shares will be issued; holders otherwise entitled to a fractional share will receive one full post-split Class A share at the participant level.
- Outstanding options, warrants, and other convertible securities will be adjusted by dividing the number of shares underlying them by four, subject to rounding under their governing terms.
Material Changes and Other Considerations
The Class A shares will continue trading on Nasdaq under ticker NIVF, with new CUSIP G0544E600. The company states that the split will not change the shares’ nil par value or the unlimited number of shares authorized under its memorandum and articles of association. The board is authorized to implement the split without shareholder approval, and no vote or consent will be sought.
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, guidance, or outlook figures. It does not describe a change in the company’s operations or provide a rationale for the split.
Important Facts for Investors to Verify
- Confirm the split’s final ratio and completion on October 12, 2026.
- Check the final post-split Class A share count, including any shares issued through convertible note exercises.
- Verify split-adjusted trading and the new CUSIP with the broker or transfer agent, and review how fractional-share treatment applies to individual holdings.
- Review the adjustment terms for any options, warrants, or convertible securities held.